Treatment
Empagliflozin clinical trials
We’re tracking 87 recruiting studies that include Empagliflozin, each written for real people, not researchers, below.
Recruiting studies
- NCT07175051RecruitingPhase 2
Testing a kidney-protecting drug in sickle cell disease
This study tests whether empagliflozin, a medicine that protects the kidneys in people with diabetes, can also protect the kidneys in people with sickle cell disease. The goal is to see if it can reduce protein in the urine, which is a sign of kidney stress.
Chicago, IllinoisAges 18–60 - NCT07292909RecruitingPhase 4
Effect of Empagliflozin on Inflammation for Coronary Patients
This trial tests if the diabetes drug empagliflozin can help reduce inflammation in people with stable coronary artery disease who are planning to have a stent placed. It may offer a new way to protect heart health.
Beirut, BeirutAges 18 years+ - NCT07331389RecruitingPhase 1
How HDM1002 interacts with common drugs and diabetes medications
This study tests how a new drug called HDM1002 interacts with common diabetes medications (metformin, empagliflozin) and other drugs like warfarin and valsartan. If you are a generally healthy adult (age 18-45) with a higher BMI, this trial helps ensure the new drug is safe when taken with other medicines.
HefeiAges 18–45 - NCT07336797RecruitingPhase 2
Empagliflozin for weight and metabolism in HIV
This trial tests if empagliflozin, a diabetes medicine, can improve weight and metabolism in people with HIV who take dolutegravir and have a high body mass index (BMI). It may help reduce weight gain linked to HIV treatment.
CairoAges 18–65 - NCT03424005RecruitingPhase 1/Phase 2
Testing new drug combinations for advanced breast cancer
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
Duarte, CaliforniaAges 18 years+ - NCT05392764RecruitingPhase 3
SGLT2 medicine for high-risk people after sudden worsening heart failure
This Phase 3 trial tests whether starting an SGLT2 inhibitor early in the hospital can improve outcomes for people at high risk after acute (sudden) heart failure. If you qualify, you would be randomized to receive the study medicine or standard care, started within 12 hours of admission.
Anjo, Aichi-kenAges 20 years+ - NCT07372040RecruitingPhase 2
Adding a Water Pill for Heart Failure in the Hospital
This trial tests if adding a diuretic (water pill) called acetazolamide to usual care can help you get rid of extra fluid faster while you are in the hospital for worsening heart failure.
TantaAges 18 years+ - NCT06674109RecruitingPhase 4
Testing a diabetes drug for gout prevention
This study tests if a type 2 diabetes medication (SGLT2 inhibitor) can help people with frequent gout flares. It aims to lower uric acid levels and reduce flare-ups.
Boston, MassachusettsAges 18–80 - NCT06024746RecruitingPhase 3
Finerenone plus SGLT2i for hospitalized heart failure
This trial tests whether adding two heart medicines together (finerenone and an SGLT2 inhibitor) helps people who are in the hospital for heart failure recover better. It may be an option for you if you are currently hospitalized and your heart stress markers are high.
Fairhope, AlabamaAges 18 years+ - NCT07053306RecruitingPhase 1
Study of SGLT2 inhibitor effects on ketoacidosis risk
This study looks at how stopping a common diabetes drug (SGLT2 inhibitor) affects the body's risk of a serious condition called ketoacidosis. It may help understand who is most at risk and how to prevent it.
San Antonio, TexasAges 30–75 - NCT05960656RecruitingPhase 1
Study of SGLT2 inhibitor effects on liver sugar production
This trial tests how stopping a type 2 diabetes medication called an SGLT2 inhibitor affects the liver's production of sugar and ketones. It may help understand better ways to manage diabetes.
San Antonio, TexasAges 30–75 - NCT07053293RecruitingEarly Phase 1
Study on diabetes medication and liver sugar production
This study tests how a type of diabetes medicine called SGLT2 inhibitors affects how the liver makes sugar. It may help researchers better understand how to manage blood sugar in people with type 2 diabetes.
San Antonio, TexasAges 30–75 - NCT04381936RecruitingPhase 3
Testing COVID-19 or pneumonia treatments in hospitalized patients
This trial tests different treatments for serious lung infections in people who are already in the hospital. It may help doctors learn which treatment works best for recovery and survival when pneumonia-like illness is suspected.
BrusselsAges birth+ - NCT05057806RecruitingEarly Phase 1
Testing how ketones may affect heart benefits in type 2 diabetes
This early study looks at people with type 2 diabetes and certain types of heart failure to see whether changes in “ketones” relate to heart benefits. It may help researchers understand who could benefit most from treatment-related metabolism changes.
San Antonio, TexasAges 18–80 - NCT05501483Recruiting
Study how fat differences may relate to type 2 diabetes
This study looks at differences in body fat to understand why some people develop type 2 diabetes. You may be asked for blood tests and health information to see if your diabetes risk and body fat patterns are linked.
StockholmAges 30–70 - NCT05715814RecruitingPhase 3
Test diabetes-pill type medicine on kidney dialysis safety
This Phase 3 trial studies the safety of an SGLT2 inhibitor (a diabetes medication that can affect kidney fluid handling) in people on peritoneal dialysis. The goal is to see how the treatment works in your type of dialysis and whether it causes any problems.
Toronto, OntarioAges 18 years+ - NCT05757791RecruitingPhase 2
Testing an SGLT2 diabetes drug for depression
This Phase 2 trial tests whether an SGLT2 medicine (like empagliflozin) can reduce symptoms of major depression. It may help people with moderate-to-severe depression who are otherwise eligible for the study.
New York, New YorkAges 18–65 - NCT05972564RecruitingPhase 1/Phase 2
SGLT2 drug trial for belly fat inflammation before weight-loss surgery
This early-phase trial tests whether an SGLT2 drug can reduce inflammation in belly fat and improve blood vessel function. It may help people with metabolic syndrome prepare for (and potentially benefit around) planned gastric bypass or sleeve surgery.
Nashville, TennesseeAges 18 years+ - NCT06055452RecruitingPhase 4
SGLT2 Inhibitors for Pre-Heart Failure with Hypertension
This trial tests if a medicine (SGLT2 inhibitor) given to people with high blood pressure and early signs of heart stress can help prevent heart failure. You may join if your blood pressure is controlled but tests show your heart is beginning to struggle.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06229678RecruitingEarly Phase 1
Ketones and diabetes drug for heart failure with weak pump
This clinical trial looks at whether adding a special diet supplement (ketones) to an SGLT2 inhibitor diabetes drug improves heart function and symptoms in people who have both type 2 diabetes and heart failure with a weakened heart muscle.
San Antonio, TexasAges 18–70 - NCT06260059RecruitingPhase 4
Jardiance for adults with congenital heart disease and reduced heart function
This study tests a medicine called Jardiance (an SGLT2 inhibitor) to see if it helps improve heart function in adults with congenital heart disease who have recently experienced a drop in their heart pumping ability. Participants will take the medication alongside standard heart failure treatments.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06355310RecruitingPhase 2
Studying an SGLT2 inhibitor for fatty liver in teens
This study tests a medication called empagliflozin (a type of SGLT2 inhibitor) to see if it can help treat fatty liver disease in teenagers and young adults. It may improve liver health and help with weight management.
Chicago, IllinoisAges 16–20 - NCT06410352RecruitingPhase 4
Weight loss methods for longer life with metabolic syndrome
This trial tests weight loss methods in people with type 2 diabetes, high blood pressure, and excess weight. It aims to see if losing 15-20% of body weight can help people live longer and healthier.
Astana, AstanaAges 35–65 - NCT06430684RecruitingEarly Phase 1
SGLT2 inhibitor trial for children with kidney disease
This trial tests a medication called SGLT2 inhibitor (a type of diabetes drug that may also help protect the kidneys) in children with chronic kidney disease. It aims to see if the drug is safe and easy to use in children ages 2–18 with moderate to severe kidney problems.
Chicago, IllinoisAges 12–25
Common questions
- Are there clinical trials studying Empagliflozin?
- Yes. Clin2 currently lists 87 recruiting studies that include Empagliflozin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Empagliflozin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Empagliflozin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Empagliflozin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.